Patient and caregiver time burden associated with anaemia treatment in different patient populations

Support Care Cancer. 2006 Dec;14(12):1195-204. doi: 10.1007/s00520-006-0075-0. Epub 2006 May 3.

Abstract

Goals: Cancer patients treated with chemotherapy often develop anaemia. This cross-sectional analysis examined the effect of anaemia treatment on patient and caregiver time and activities.

Materials and methods: The analysis included 9,920 patients from 646 US outpatient oncology centres. Patients completed a survey that contained questions about travel time, total time for the visit and other impacts.

Results: The mean time taken for a single clinic visit to receive anaemia treatment was 2.2 h. On average, patients receiving epoetin alfa required 17.6 h more than patients receiving darbepoetin alfa to complete a course of anaemia treatment. All patients in the study reported that they had to adjust at least one activity as a result of clinic visits. Older patients, women and patients from low-income areas were more likely to be accompanied during clinic visits.

Conclusions: Reducing the number of clinic visits needed for anaemia treatment by using darbepoetin alfa may benefit patients.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Anemia / drug therapy*
  • Caregivers*
  • Cross-Sectional Studies
  • Darbepoetin alfa
  • Employment
  • Epoetin Alfa
  • Erythropoietin / analogs & derivatives
  • Erythropoietin / therapeutic use
  • Female
  • Humans
  • Male
  • Middle Aged
  • Neoplasms / complications*
  • Recombinant Proteins
  • Regression Analysis
  • Time Factors

Substances

  • Recombinant Proteins
  • Erythropoietin
  • Darbepoetin alfa
  • Epoetin Alfa